Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/59559
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Bortezomib in multiple myeloma |
Autor: | Mateos, Maria Victoria; San Miguel, Jesús F. CSIC ORCID | Fecha de publicación: | 2007 | Editor: | Elsevier | Citación: | Best Practice and Research: Clinical Haematology 20(4): 701-715 (2007) | Resumen: | Multiple myeloma (MM) remains an incurable disease, and novel agents are therefore needed to improve outcome. Bortezomib is the first proteasome inhibitor to be approved by the US Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products for the treatment of refractory/relapsed MM. Bortezomib has demonstrated significant anti-myeloma activity as a single agent in refractory/relapsed MM. When used in combination with other agents, responses have suggested the possibility of chemosensitization and synergy. All these facts have been the rationale for the use of bortezomib-based regimens as upfront treatment in young and elderly newly diagnosed MM patients. Furthermore, bortezomib does not appear to have an adverse effect on subsequent stem-cell collection. Bortezomib is well tolerated; most side-effects are only mild to moderate and manageable. Practical management of these side-effects is given so that they can be recognized and minimized by dose modification or concomitant therapy. © 2007 Elsevier Ltd. All rights reserved. | URI: | http://hdl.handle.net/10261/59559 | DOI: | 10.1016/j.beha.2007.09.003 | Identificadores: | doi: 10.1016/j.beha.2007.09.003 issn: 1521-6926 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
35
checked on 10-abr-2024
WEB OF SCIENCETM
Citations
30
checked on 27-feb-2024
Page view(s)
323
checked on 19-abr-2024
Download(s)
149
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.